Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10778839 | 0.83 | SMN1; SMN2 (0.52) | NMT1HSD17B10TDP1 | |
| Hydrochloric Acid SCHEMBL11408619 | 0.82 | RAD51 (0.55) | ALDH1A1RAD51MMP1MMP2MMP9 | |
| SCHEMBL2817252 | 0.81 | SMN1; SMN2 (0.68) | — | |
| SCHEMBL201938 | 0.80 | ALDH1A1 (0.64) | ALDH1A1KDM4EHSD17B10TDP1 | |
| SCHEMBL1548460 | 0.80 | PEPD (0.59) | ALDH1A1ALDH5A1ABATKDM4EHSD17B10 | |
| SCHEMBL1877254 | 0.80 | ALDH1A1 (0.48) | ALDH1A1RAD51MMP1MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL11405284 | 0.80 | SMN1; SMN2 (0.50) | NMT1HSD17B10TDP1 | |
| SCHEMBL16316028 | 0.78 | NPC1 (0.59) | ALDH1A1KDM4ETDP1 | |
| Ammonia Solution, Strong SCHEMBL7802754 | 0.78 | ALDH1A1 (0.62) | ALDH1A1KDM4EHSD17B10TDP1 | |
| SCHEMBL1916615 | 0.78 | POLB (0.56) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250269050-A1 | CYCLIC DICHALCOGENIDE ADC LINKER UNITS AND USES THEREOF | THORN SESHOLD OLIVER (DE) | 2025-08-28 | — | — | US | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024059808-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-11851446-B2 | Probes for imaging Huntingtin protein | CHDI FOUNDATION, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11801315-B2 | Radioligands for myelin | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2015154022-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015144933-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2015-10-01 | — | — | WO | disclosed |
| US-20140309427-A1 | Substituted Pyran Derivatives | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-16 | — | — | US | disclosed |
| WO-2014160028-A1 | PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2409977-A1 | AMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-7834002-B2 | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| WO-2009095394-A1 | DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-08-06 | — | — | WO | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-7074243-B2 | N-benzyl-m-phenylenediamine derivatives and dyes containing said compounds | WELLA AG (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20030182735-A1 | N-benzyl-m-phenylenediamine derivatives and dyes containing said compounds | WELLA AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851446-B2 | Probes for imaging Huntingtin protein | HTT, HYPK, HSPBP1 | ALDH1A1 3976/4885CYP2A6 4875/4885ALDH5A1 4078/4885 |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | ALDH1A1 2654/4885CYP2A6 3946/4885ALDH5A1 3501/4885 |
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | ALDH1A1 3134/4885CYP2A6 3274/4885ALDH5A1 3713/4885 |
| US-20030182735-A1 | N-benzyl-m-phenylenediamine derivatives and dyes containing said compounds | KRT18, VIM, KPNB1 | ALDH1A1 601/4885CYP2A6 3661/4885ALDH5A1 1490/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | ALDH1A1 381/4885CYP2A6 1495/4885ALDH5A1 880/4885 |
| US-20140309427-A1 | Substituted Pyran Derivatives | SLC18A2, SLC6A4, SLC6A3 | ALDH1A1 772/4885CYP2A6 219/4885ALDH5A1 503/4885 |
| US-11801315-B2 | Radioligands for myelin | MAG, PMP22, MYT1 | ALDH1A1 3084/4885CYP2A6 4601/4885ALDH5A1 1595/4885 |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | ALDH1A1 4369/4885CYP2A6 4370/4885ALDH5A1 3501/4885 |
| US-20250269050-A1 | CYCLIC DICHALCOGENIDE ADC LINKER UNITS AND USES THEREOF | CCL2, UACA, CAD | ALDH1A1 3319/4885CYP2A6 4479/4885ALDH5A1 3068/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | ALDH1A1 4369/4885CYP2A6 4370/4885ALDH5A1 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.